Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone and Omacor for VLDL transport in metabolic syndrome with NAFLD
ACTRN12609000620224Phase 4Terminated
- Sponsor
- Professor Gerald Watts
- Start
- Aug 2009
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pioglitazone and omega-3-acid triglycerides in cardiometabolic risk (CMR) and metabolic dysfunction-associated steatotic liver disease (MASLD) (4 arms), sponsored by Professor Gerald Watts. Primary endpoints: VLDL transport and VLDL-apolipoprotein B production. Started Aug 2009; status: terminated.
02
Drugs
pioglitazoneomega-3-acid triglycerides
03
Conditions
cardiometabolic risk (CMR)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ACTRN12609000620224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000620224.